Sanofi VI went to Jinbo and continued to make innovative achievements in new rare diseases
梦中的那片蓝
发表于 2023-11-7 18:55:30
1263
0
0
China Net Finance, November 7th (Reporter Jia Yujing) - Recently, the world's leading innovative pharmaceutical and health enterprise Sanofi VI went to the China International Fair and unveiled several similar groundbreaking products in the innovation pipeline and immune fields of the group. Among them, the world's first siRNA therapy applied in the field of hemophilia is the innovative drug Fitusiran, and the latest approved new generation enzyme replacement therapy (ERT) drug for the treatment of Pompeii disease is resistant and praised; Reg; It is particularly worth mentioning.
It is reported that hemophilia is a hereditary hemorrhagic disease that lasts for a lifetime. Patients are referred to as "glassy people", and due to a natural lack of specific coagulation factors in the body, they suffer from "continuous blood flow" throughout their lives. As the largest disease among rare diseases, the incidence of hemophilia in China is approximately (2.73-3.09) per 100000.
Currently, the standard treatment for hemophilia is to receive 2-3 prophylactic intravenous injections of coagulation factors per week. However, patients still face high infusion frequency, poor treatment compliance, inability to ensure continuous and sufficient preventive treatment, and high disability rates, resulting in huge unmet needs. Sanofi is developing a new drug, Fitusiran, which has brought a breakthrough prevention and treatment plan for hemophilia A/B patients. It is reported that Fitusiran is the world's first and only siRNA hemophilia treatment drug, with injection frequency reduced by more than 90% compared to standard factor prophylactic treatment.
Sun Jing, a professor of hematology at Southern Hospital of Southern Medical University, stated that Fitusiran is a preventive treatment plan available for all types of hemophilia patients, and is effective for both type A and type B hemophilia patients with or without inhibitors. By reducing the level of antithrombin III, the annual bleeding rate of patients can be reduced by up to 90%.
Compared to the current routine treatment method of intravenous injection 3-4 times a week, Fitusiran only needs to undergo a minimum of 6 subcutaneous injections per year, greatly reducing the treatment burden on patients. As a healthcare worker, Sun Jing is pleased to see the upgrading and iteration of hemophilia treatment technology. In her opinion, preventive treatment is more effective in preventing disability than on-demand treatment.
Guan Tao, the founder and chairman of the Blood Friends Home and the chairman of the Beijing Blood Friends Home Rare Disease Care Center, stated that the treatment of hemophilia in China, especially in terms of medication, has undergone a change from "immortality" to "no pain", and will continue to pursue "no disability". Adequate prevention and treatment is the only way to achieve 'no disability' for hemophilia. Fitusiran's convenient and easy to use administration has fundamentally changed patients' diagnosis and treatment habits, opening a new era for hemophilia prevention and treatment
In addition to developing a new drug, Fitusiran, Sanofi's new generation of enzyme replacement therapy (ERT) drugs for the treatment of Pompeii disease are highly resistant; Reg; We also took advantage of our efforts to complete the magnificent transformation from "exhibits" to "products" at the Expo. It is reported that Nai Er Zan& Reg; Last year, it made its debut in China and was approved in China on the eve of this year's promotion.
Public information shows that Pompeii's disease generally refers to glycogen storage disease type II. The neurological manifestations of this disease are mainly motor disorders, with muscle weakness in the limbs, muscular atrophy, pseudohypertrophy, and other muscle diseases being more common. According to Zhao Zhongbo, chief physician of the Department of Neurology at Huashan Hospital affiliated with Fudan University, Pompeii disease is an autosomal recessive genetic disease and an extremely rare disease with a very small number of patients. If left untreated, it can lead to irreversible and progressive damage to multiple organs and systems, requiring long-term dependence on wheelchairs and ventilators, and leading to premature death.
In October of this year, Sanofi's next-generation enzyme replacement therapy (ERT) drug resistance was praised; Reg; Approved by the National Drug Administration (NMPA) of China for long-term treatment of Pompeii disease patients. According to the introduction, Nai Er Zan& Reg; Awarded the title of "breakthrough therapy" by the FDA, its 15-fold enzyme transporter level can increase cell uptake of enzymes, better improve respiratory and motor function in patients with Pompeii disease, with good safety, and is aimed at becoming a new generation of standard treatment plan.
Professor Fu Lijun from the Shanghai Children's Medical Center affiliated with Shanghai Jiao Tong University School of Medicine stated that patients with Pompeii disease also look forward to more innovative drugs to bring them better quality of life benefits when receiving treatment and delaying disease progression. Speak of patience and praise& Reg; Approved in China, Fu Lijun stated that clinical data shows that the drug is highly recommended; Reg; It can be more efficiently targeted for uptake to clear glycogen, improve respiratory function and exercise ability of patients with Pompeii disease, and improve the quality of life of patients with Pompeii disease. I am glad to see the new generation of ERT drugs for Pompeii disease approved in China, and I hope to let the public know about Pompeii disease and its new therapies through the platform of the CIIE
Xie Lijuan, General Manager of Sanofit China, stated that with the approval of NIZAN in China, Chinese patients with Pompeii disease will receive a new revolutionary treatment and new hope. Nerozan has also expanded Sanofi's rare disease product portfolio in China - to date, it has covered lysosomal storage disorders such as Gaucher's disease, Pompeii's disease, Fabry's disease, and mucopolysaccharide storage type I, as well as neuroscience diseases such as multiple sclerosis and frostbite. In the future, Sanofi will continue to enhance its product line for rare diseases, introduce innovative and high-quality drugs to Chinese patients, and work together to build an ecosystem covering prevention and treatment, helping rare disease patients face health challenges and regain their lives
The CIIE is an open platform for innovation and cooperation, seeking opportunities together. Patients with rare diseases should also share their health with the general public in the new era. In addition to therapeutic innovation, breakthrough policy mechanism innovation is also needed to ensure drug accessibility and affordability, ultimately helping patients achieve sustained benefits. At this year's CIIE, Sanofi also assisted the Koude Rare Disease Center and several authoritative experts in the field of rare diseases to jointly launch the "China Rare Disease Legislative Protection Exploration Initiative Action", exploring the "Chinese model" of rare disease protection for the vast number of rare disease patients through product and institutional innovation.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Financial One Account reduces losses by nearly 60%, and overseas business becomes a new growth point
- Ideal new! Meituan Wang Xing's Rare Comment: This is "the car that employees make for themselves"
- Analysts say Apple's new 11 inch iPad Pro may be out of stock in the early stages of its launch
- Luckin's return to losses, Starbucks's rare sharp decline, Q1 2024 coffee industry competition intensifies?
- Apple launches new products! The Thinnest iPad in History Appears
- Apple's rare apology
- NIO Innovation Technology Day releases achievements such as the Tianshu operating system and self-developed chips
- Apple Rare Layoffs! Its service department reportedly laid off about 100 people, involving teams such as Apple Books
- Will the new button added by Apple on iPhone 16 become the gateway for future AI?
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
8月のトヨタ自動車(ダイハツ自動車と日野自動車を除く、レクサスを含む)の世界生産台数は前年同月比11.2%減の709571台、世界販売台数は前年同月比3.1%減の826863台だった。 日本本土市場では、トヨタ自動車の8月 ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏